Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.verified

MDGL

Price:

$279.125

Market Cap:

$5.95B

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.[Read more]

Industry

Biotechnology

IPO Date

2007-02-06

Stock Exchange

NASDAQ

Ticker

MDGL

The Enterprise Value as of June 2024 (TTM) for Madrigal Pharmaceuticals, Inc. (MDGL) is 5.44B

According to Madrigal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.44B. This represents a change of 34.37% compared to the average of 4.05B of the last 4 quarters.

Madrigal Pharmaceuticals, Inc. (MDGL) Historical Enterprise Value (quarterly & annually)

How has MDGL Enterprise Value performed in the past?

The mean historical Enterprise Value of Madrigal Pharmaceuticals, Inc. over the last ten years is 1.58B. The current 5.44B Enterprise Value has changed 34.41% with respect to the historical average. Over the past ten years (40 quarters), MDGL's Enterprise Value was at its highest in in the December 2022 quarter at 4.72B. The Enterprise Value was at its lowest in in the March 2016 quarter at -39003272.80.

Quarterly (TTM)
Annual

Average

1.58B

Median

1.27B

Minimum

-28221103.00

Maximum

4.69B

Madrigal Pharmaceuticals, Inc. (MDGL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Madrigal Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.42%

Maximum Annual Enterprise Value = 4.69B

Minimum Annual Increase = -231.29%

Minimum Annual Enterprise Value = -28221103.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20234.34B-7.48%
20224.69B243.59%
20211.37B-17.92%
20201.66B22.66%
20191.36B14.56%
20181.18B27.00%
2017932.44M2.42%
201637.05M-231.29%
2015-28221103.00-112.33%
2014228.88M-34.01%

Madrigal Pharmaceuticals, Inc. (MDGL) Average Enterprise Value

How has MDGL Enterprise Value performed in the past?

The current Enterprise Value of Madrigal Pharmaceuticals, Inc. (MDGL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

3.47B

5-year avg

2.68B

10-year avg

1.58B

Madrigal Pharmaceuticals, Inc. (MDGL) Enterprise Value vs. Peers

How is MDGL’s Enterprise Value compared to its peers?

Madrigal Pharmaceuticals, Inc.’s Enterprise Value is greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than TG Therapeutics, Inc. (2.59B), greater than Terns Pharmaceuticals, Inc. (468.91M), greater than Hepion Pharmaceuticals, Inc. (-7073438.00), less than Viking Therapeutics, Inc. (5.51B), less than Sarepta Therapeutics, Inc. (12.50B), greater than PTC Therapeutics, Inc. (2.62B), greater than Day One Biopharmaceuticals, Inc. (831.02M), greater than X4 Pharmaceuticals, Inc. (164.71M), greater than Inozyme Pharma, Inc. (315.19M), greater than Acumen Pharmaceuticals, Inc. (140.16M), greater than Mereo BioPharma Group plc (554.91M), greater than 89bio, Inc. (666.65M), greater than Pliant Therapeutics, Inc. (651.00M), greater than Arcellx, Inc. (2.81B), greater than Stoke Therapeutics, Inc. (671.58M), greater than Krystal Biotech, Inc. (4.73B), greater than Iovance Biotherapeutics, Inc. (2.23B),

Build a custom stock screener for Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Madrigal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Madrigal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Madrigal Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Madrigal Pharmaceuticals, Inc. (MDGL)?

What is the 3-year average Enterprise Value for Madrigal Pharmaceuticals, Inc. (MDGL)?

What is the 5-year average Enterprise Value for Madrigal Pharmaceuticals, Inc. (MDGL)?

How does the current Enterprise Value for Madrigal Pharmaceuticals, Inc. (MDGL) compare to its historical average?